Moderna
MRNA
Moderna (MRNA) earnings history
Most recent quarter
- Fiscal period
- Q2 2026
- Period end
- Jun 30, 2026
- EPS actual
- −$1.97
- EPS estimate
- −$1.98
- EPS surprise
- +0.53%
- Revenue surprise
- +19.59%
- Revenue
- $145.0M
- Revenue estimate
- $121.2M
- Reported
- Jul 31, 2026
Earnings history
| Period | Reported | EPS estimate | EPS actual | Surprise | Revenue | Filing |
|---|---|---|---|---|---|---|
| Q2 2026 | Jul 31, 2026 | −$1.98 | −$1.97 | +0.53% | $145.0M | SEC |
| Q1 2026 | May 1, 2026 | −$4.45 | −$3.40 | +23.53% | $389.0M | SEC |
| Q4 2025 | Feb 13, 2026 | −$2.54 | −$2.11 | +17.07% | $678.0M | SEC |
| Q3 2025 | Nov 6, 2025 | −$1.87 | −$0.51 | +72.79% | $1.0B | SEC |
| Q2 2025 | Aug 1, 2025 | −$2.99 | −$2.13 | +28.75% | $142.0M | SEC |
| Q1 2025 | May 1, 2025 | −$3.12 | −$2.52 | +19.13% | $108.0M | SEC |
| Q4 2024 | Feb 14, 2025 | −$2.68 | −$2.91 | −8.57% | $966.0M | SEC |
| Q3 2024 | Nov 7, 2024 | −$1.80 | $0.03 | +101.66% | $1.9B | SEC |
| Q2 2024 | Aug 1, 2024 | −$3.35 | −$3.33 | +0.54% | $241.0M | SEC |
| Q1 2024 | May 2, 2024 | −$3.56 | −$3.07 | +13.68% | $167.0M | SEC |
| Q4 2023 | Feb 22, 2024 | −$0.99 | $0.55 | +155.74% | $2.8B | SEC |
| Q3 2023 | Nov 2, 2023 | −$1.93 | −$9.53 | −393.19% | $1.8B | SEC |
| Q2 2023 | Aug 3, 2023 | −$3.93 | −$3.62 | +8.00% | $344.0M | SEC |
| Q1 2023 | May 4, 2023 | −$1.75 | $0.19 | +110.87% | $1.9B | SEC |
| Q4 2022 | Feb 23, 2023 | $4.60 | $3.61 | −21.54% | $5.1B | SEC |
| Q3 2022 | Nov 3, 2022 | $3.30 | $2.53 | −23.29% | $3.4B | SEC |
| Q2 2022 | Aug 3, 2022 | $4.58 | $5.24 | +14.33% | $4.7B | SEC |
| Q1 2022 | May 4, 2022 | $5.37 | $8.58 | +59.69% | $6.1B | SEC |
| Q4 2021 | Feb 24, 2022 | $9.96 | $11.29 | +13.33% | $7.2B | SEC |
| Q3 2021 | Nov 4, 2021 | $8.97 | $7.70 | −14.19% | $5.0B | SEC |
Quarterly revenue
Frequently asked questions
When did Moderna (MRNA) last report earnings?
Moderna last reported on Jul 31, 2026, covering fiscal Q2 2026.
Did MRNA beat earnings estimates?
Yes. Moderna reported EPS of −$1.97 for Q2 2026 against a −$1.98 estimate — a 0.53% beat.
How much revenue did MRNA report last quarter?
Moderna reported $145.0M in revenue for Q2 2026, against a consensus estimate of $121.2M.
Earnings figures may be restated, revised or corrected by the issuer. Past results do not indicate future performance.
This page is for informational purposes only. Nothing on it is a recommendation, solicitation or offer to buy or sell any security, nor investment, legal or tax advice. Light Horse Securities Inc does not verify third-party data and is not responsible for its accuracy, completeness or timeliness.